ECP Treatment Shows Alzheimer's Cognitive Benefits
A clinical trial finds external counterpulsation may improve cognitive function in patients with early Alzheimer's disease.
Updated on Oct. 20, 2026 in Alzheimer’s
Live Poll
Would you trust a non-invasive physical therapy for Alzheimer's over traditional pharmaceutical treatment options?
A clinical trial involving 190 patients found that external counterpulsation treatment helps improve cognitive function in individuals with early Alzheimer's disease or mild cognitive impairment. On average, participants gained five points on standard cognitive assessment scales during the six-month study.
Why it matters
The treatment aims to enhance blood flow to the brain, which is often diminished in dementia patients. This method offers a potential non-invasive alternative to help maintain arterial function and slow cognitive decline.
The clinical trial included 190 patients, with 84 percent of those in the full-pressure group showing cognitive improvements. Six months after treatment ended, 75 percent of patients still maintained cognitive gains from the start of the study.
The players
Renew Research
Renew Research is the developer seeking US Food and Drug Administration approval for the external counterpulsation device.
The details
The procedure utilizes squeezable cuffs to compress the lower body, effectively propelling blood toward the heart. Patients underwent 35 sessions over the six-month trial period at a frequency of 3 to 5 times per week.
Timeline
1970s: Refinement of external counterpulsation technology.
Six months: Duration of the clinical trial treatment period.
Six months after trial: Duration of sustained cognitive improvements.
Last year: Company sent a letter to the FDA regarding approval delays.
Health Landscape
The ECP device is currently navigating the US Food and Drug Administration's medical device approval process, which regulates market entry for new clinical technologies. This trial marks a significant step toward integrating non-pharmacological interventions into standard dementia care protocols.
Patients currently have limited options for managing early-stage cognitive impairment, making these results a potential future avenue for treatment. However, since the device lacks FDA approval, it remains unavailable for clinical use as an Alzheimer's therapy within the United States.
The takeaway
This trial suggests that improving arterial blood flow could be a viable strategy for addressing the symptoms of dementia. Families should continue consulting with medical professionals regarding established care plans while new therapies await formal regulatory clearance.
Further reading
For additional context on current research and clinical milestones, explore the latest updates in Alzheimer’s.
Live Poll
Would you trust a non-invasive physical therapy for Alzheimer's over traditional pharmaceutical treatment options?
